Erratum to: Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component

Inkeun Park · Yong Mee Cho · Jae-Lyun Lee · Jin-Hee Ahn · Dae-Ho Lee ·
Cheryn Song · Jun-Hyuk Hong · Choung-Soo Kim · Hanjong Ahn

Published online: 10 August 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: J Cancer Res Clin Oncol (2013)
139:817–827
DOI 10.1007/s00432-013-1386-4

Unfortunately, in the original version of this article contained error. The authors would like to correct the misinformed study in the published article.

On p. 826, in Table 5, 1st row referring Staehler et al.'s study, “sunitinib after failure to GD” should be “sorafenib after failure to GD.” The amended Table 5 is provided on the next page.

The online version of the original article can be found under doi:[10.1007/s00432-013-1386-4](https://doi.org/10.1007/s00432-013-1386-4).

I. Park · J.-L. Lee (✉) · J.-H. Ahn · D.-H. Lee
Department of Oncology, Asan Medical Center, University
of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil,
Songpa-gu, Seoul 138-736, Korea
e-mail: jaelyun@amc.seoul.kr

I. Park
e-mail: ingni79@hanmail.net

J.-H. Ahn
e-mail: drjiny@amc.seoul.kr

D.-H. Lee
e-mail: leedaeho@amc.seoul.kr

Y. M. Cho
Department of Pathology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, Korea
e-mail: yongcho@amc.seoul.kr

C. Song · J.-H. Hong · C.-S. Kim · H. Ahn
Department of Urology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, Korea
e-mail: cherynsong@amc.seoul.kr

J.-H. Hong
e-mail: jhhong@amc.seoul.kr

C.-S. Kim
e-mail: cskim@amc.seoul.kr

H. Ahn
e-mail: hjahn@amc.seoul.kr

Table 5 Select reports on systemic treatment for SRCC

Author	Methods	PSC	No. of pts	Stage	Treatment (no. of patients treated)	Response rate	Stable disease	Median OS (months)
Sella et al. (1987)	R	Mayo clinic criteria	44	I–IV (I–III, 19; IV, 25)	Doxorubicin-containing CHT ^b (8) No doxorubicin CHT (5) Hormone (8) Hormone + no doxorubicin CHT (6) IFN (4)	25 % 0 0 0 0	NR	2.0 1.5 4.0 4.0 5.5 6.6 (in all)
Culine et al. (1995)	R	>60 %	14	Recurrent or IV	Doxorubicin-containing CHT (8)	38 %	0	12.0 (range 33–9)
Wu et al. (1998)	R	100 %	7	IV	IFN (4) IFN or IL-2 (<i>n</i> = 7)	0 0	0 NR	0 13.8
Cangiano et al. (1999)	R	Not specified but <50 % in 12 and >50 % in 19 patients	31	I–IV (I–III, 3; IV, 28)	Variable immunotherapy (HD IL-2, LD IL-2/IFN, TIL-based therapy, and dendritic cell vaccine) (24)	13 %	NR	48 % at 1 year
Mian et al. (2002) ^a	R	Not specified (>0–100 %)	108	I–IV (locoregional 39, metastatic 69)	IFN-based therapy (77)	31 %	NR	9
Escudier et al. (2002)	P	>0–100 %	23	IV	IL-2-based therapy (35) Chemotherapy (26) DI (23)	33 % 19 % 0	26 %	3.9
Nanus et al. (2004)	R	Not specified	10	IV	GD (10)	33 %	20 %	3.5
Roubaud et al. (2011)	R	Not specified	6	IV	GD (6)	0	33 %	NR
Haas et al. (2012)	P	10–100 %	38	IV	GD (38)	13 %	26 %	8.8
Kwak et al. (2007)	R	Not specified	32	IV	INF- α or 5-FU/IL-2/IFN- α	NR	NR	10
Golshayan et al. (2009)	R	3–90 % (a median of 14 %), only 13 patients had PSC >20 %	43	IV	Sunitinib (21) Sorafenib (12) Bevacizumab (8) Sunitinib + bevacizumab (2) Sunitinib (34)	29 % 8 % 13 % 0 15 %	43 % 50 % 50 % 100 % 50 %	11.8 10.5 17.4 10
Molina et al. (2011)	R	2–100 % (median 20 %)	63	IV	Sorafenib (9) Temozolimus (7) Immunotherapy (IFN or IL-2, 20)	0 14 % 5 %	NR 14 % 40 %	

Table 5 continued

Author	Methods	PSC	No. of pts	Stage	Treatment (no. of patients treated)	Response rate	Stable disease	Median OS (months)
Staehler et al. (2010)	P	100 %	15	IV	GD	0	NR	NR
Michaelson et al. (2010)	P	Not specified	9	IV	Sorafenib after failure to GD	11 %		8.0
Current study	R	≥25 %	37	IV	Gemcitabine + sunitinib (9) Sunitinib (10) Tensirolimus (2) Everolimus (1) INF- α or 5-FU/IL-2/IFN- α (10)	33 % 20 % 0 0 0	NR 40 % 0 100 % 0	NR 5.9

PSC percentage of sarcomatoid component, R retrospective study, P prospective study, CHT chemotherapy, NR not reported, HDIL-2 high-dose interleukin-2, LDIL-2 low-dose interleukin-2, TIL tumor-infiltrating lymphocytes, INF interferon, DI doxorubicin + ifosfamide, GD gemcitabine + doxorubicin, 5-FU 5-fluorouracil

^a Eighteen different regimens of immunotherapy and/or chemotherapy were used. Total number of patients received therapy is greater than 100 % because more than half the patients received multiple regimens

^b Doxorubicin-containing chemotherapy includes CYVADIC (cyclophosphamide + vincristine + doxorubicin + dacarbazine), DECAV (cisplatin + dacarbazine + cyclophosphamide + doxorubicin + vindesine), and DI (doxorubicin + ifosfamide)